Literature DB >> 16837775

Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma.

Anca Sterian1, Takatsugu Kan, Agnes T Berki, Yuriko Mori, Andreea Olaru, Karsten Schulmann, Fumiaki Sato, Suna Wang, Bogdan Paun, Kun Cai, James P Hamilton, John M Abraham, Stephen J Meltzer.   

Abstract

OBJECTIVE: Mortality due to esophageal adenocarcinoma has risen markedly, but the molecular mechanisms underlying this carcinogenesis are still incompletely understood. Findings from loss of heterozygosity (LOH) studies have suggested that the long arm of chromosome 4 might harbor tumor suppressor genes relevant to esophageal adenocarcinoma.
METHODS: We performed LOH analysis of 4q in esophageal adenocarcinomas. Regions of LOH were further evaluated by studying two candidate tumor suppressor genes, hCDC4 and CARF, located within them.
RESULTS: 54% of the adenocarcinomas examined showed allelic deletion. LOH was observed in 53, 40, 32, 38, and 27% of tumors at positions D4S1554 (the locus of CARF), D4S1572, D4S1548, D4S2934, and D4S3021, respectively. An area of allelic deletion (spanning 3 million bases) was identified at 4q31.1-3 in 37% of tumors. This region harbors a candidate tumor suppressor gene: hCDC4. However, sequencing of the coding regions of CARF and hCDC4 at 4q35 and 4q31, respectively, did not identify mutations.
CONCLUSIONS: Our findings demonstrate frequent LOH in esophageal adenocarcinoma at several loci including a novel area of allelic deletion at 4q31.1-3. The results imply that mutational or other alterations at these loci may be involved in the pathogenesis of esophageal adenocarcinoma. Candidate tumor suppressor genes located within these regions merit further study. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837775     DOI: 10.1159/000094444

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

1.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

2.  Malignant tumors and forensics--dilemmas and proposals.

Authors:  Zoran Budimlija; Connie Lu; Grace Axler-DiPerte; Jessica Seifarth; Dorota Popiolek; Franz Fogt; Mechthild Prinz
Journal:  Croat Med J       Date:  2009-06       Impact factor: 1.351

3.  Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Authors:  Shahab Akhoondi; Linda Lindström; Martin Widschwendter; Martin Corcoran; Jonas Bergh; Charles Spruck; Dan Grandér; Olle Sangfelt
Journal:  Breast Cancer Res       Date:  2010-12-01       Impact factor: 6.466

4.  FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients.

Authors:  Martin Hagedorn; Maylis Delugin; Isabelle Abraldes; Nathalie Allain; Marc-Antoine Belaud-Rotureau; Michelle Turmo; Claude Prigent; Hugues Loiseau; Andréas Bikfalvi; Sophie Javerzat
Journal:  Cell Div       Date:  2007-02-27       Impact factor: 5.130

Review 5.  PI(3,4)P2 Signaling in Cancer and Metabolism.

Authors:  Luca Gozzelino; Maria Chiara De Santis; Federico Gulluni; Emilio Hirsch; Miriam Martini
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.